Pulmonx Corporation (LUNG) Dividend History

Pulmonx Corporation develops minimally invasive lung therapies, focusing on bronchoscopic procedures to treat severe emphysema. Its flagship product, Zephyr Endobronchial Valve, is used to improve breathing by reducing lung hyperinflation. The company aims to offer less invasive alternatives to traditional surgery for patients with advanced lung disease.

700 Chesapeake Drive, Redwood City, CA, 94063
Phone: 650-364-0400
Website:

Dividend History

Pulmonx Corporation currently does not pay dividends

Company News

  • 5 Medical Info Systems Stock to Buy for a Stable Portfolio

    We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

    Zacks Investment Research
    Featured Companies: ENOV HIMS LAB PHR
  • How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%

    The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

    Zacks Investment Research
  • 5 Medical Info Systems Stocks to Buy for Stable Returns

    We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.

    Zacks Investment Research
    Featured Companies: BFLY DH ENOV HIMS
  • Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on May 6, 2024 to Mehul Joshi in connection with his appointment as the Chief Financial Officer of Pulmonx in April 2024.

    GlobeNewswire Inc.
  • Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?

    The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

    Zacks Investment Research
Dividend data last updated 06/07/2025 02:47:37 UTC